Urinary tract infections (UTIs) account for over 8 million clinic and ER visits every year.
Under-diagnosis can lead to under-treatment, an impediment to responsible antibiotic stewardship. A test needs to identify when pathogens are present, which are present, and how much is present, all before identifying what treatment may work.
Now, there’s a test that identifies and quantifies infectious bacteria and the antibiotics they’re susceptible to: UTIP™ and polyMIC™ help ensure patients get the right diagnosis and prescription, right from the start. In a single day.
UTIP and polyMIC require one urine sample to determine the microbial nature of the infection.
CirrusDx combines molecular testing—UTIP—to identify and quantify each microbe, with culture-based testing—polyMIC—to look for in-vitro susceptibility, direct from the patient sample.
UTIP and polyMIC pinpoint offending organisms, regardless how many are identified, and the antibiotics capable of clearing the entire infection. For treatment decisions that are validated by science.
Up to 30% of UTIs are polymicrobial, driven by biofilm-producing bacteria. Traditional culture-only testing leaves clinicians with no more than a “mixed flora” result, and ultimately empirical treatment.
CirrusDx is bringing diagnostic tools closer to the patient to counteract the challenge presented by antibiotic stewardship and empirical treatment.
We are creating vertically integrated diagnostic solutions for UTIs and beyond, proper diagnostic tools that lead to proper treatment. Instrumentation, connectivity, and advanced methods to connect our laboratory to your practice.
